Summary

Dementia-related myoclonus is a common but heterogeneous motor manifestation observed across Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), frontotemporal dementia (FTD), and rapidly progressive dementias such as sporadic Creutzfeldt–Jakob disease (sCJD). This report evaluated whether myoclonus should be interpreted primarily as (i) a biomarker of disease progression, (ii) a marker of biological aggressiveness, or (iii) a distinct hyperexcitable subtype.

Across epidemiological studies, myoclonus is substantially over-represented in neurodegenerative dementias compared with normal ageing, but its timing and distribution vary markedly by syndrome and phenotype. In sporadic late-onset AD, myoclonus typically emerges later in the disease course and tracks with advancing network dysfunction. In contrast, earlier occurrence in early-onset or genetically determined AD, as well as its prominence in rapidly progressive dementias such as sCJD, suggests a contextual association with more aggressive disease biology. However, marked heterogeneity across dementia syndromes—particularly within the FTD spectrum—argues against a uniform interpretation of myoclonus as a cross-dementia biomarker or subtype.

Electrophysiological evidence provides the strongest mechanistic insight. Dementia-related myoclonus is most often consistent with cortical myoclonus, characterised by short EMG bursts, jerk-locked cortical discharges, and, in some cases, enlarged somatosensory evoked potentials. More broadly, a substantial body of work demonstrates that a subset of dementia patients—especially in AD—exhibits measurable cortical hyperexcitability, including subclinical epileptiform activity detectable on prolonged or sleep-inclusive EEG. This hyperexcitable state has been associated with faster cognitive decline in some longitudinal cohorts. However, the strongest evidence concerns epileptiform activity and seizures rather than myoclonus itself, limiting direct inference about myoclonus as an independent prognostic marker.

From a conceptual standpoint, the most coherent model is a three-stage causal framework: neurodegenerative pathology drives network-level hyperexcitability, which in turn may manifest clinically as myoclonus. Within this framework, myoclonus is best interpreted as a visible readout of an underlying network state rather than as a primary driver of disease progression.

The evidence supporting myoclonus as a biomarker of progression remains limited. Longitudinal studies rarely demonstrate that myoclonus independently predicts cognitive or functional decline after adjustment for confounders. The case for myoclonus as a marker of aggressiveness is stronger but remains indirect, relying on its enrichment in clinically severe phenotypes such as early-onset AD and prion disease. The most mechanistically persuasive interpretation is that myoclonus forms part of a broader hyperexcitable phenotype; however, this subtype remains provisional due to the absence of validated diagnostic criteria, standardised phenotyping, and reproducibility data.

Clinically, myoclonus has important diagnostic and management implications. Its presence should lower the threshold for electrophysiological investigation, particularly prolonged or sleep-inclusive EEG, and prompt consideration of seizure overlap, rapidly progressive dementias, and medication-related causes. Prognostically, it functions as a warning sign of cortical hyperexcitability or disease severity rather than a validated standalone predictor. Therapeutically, management is largely symptomatic and extrapolated from cortical myoclonus and epilepsy literature, with levetiracetam often preferred in cognitively vulnerable populations, although robust dementia-specific efficacy data are lacking.

The current evidence base is limited by methodological heterogeneity, ascertainment bias, inconsistent phenotyping, and reliance on indirect or non-dementia-specific data. Crucially, most studies do not distinguish clearly between progression, aggressiveness, and subtype constructs, preventing definitive conclusions.

In synthesis, dementia-related myoclonus is best understood as a clinically salient manifestation of cortical network hyperexcitability that, in certain contexts, correlates with more severe or rapidly progressive disease. It does not yet meet evidentiary standards for a universal biomarker of progression or a validated dementia subtype. Future research should prioritise standardised phenotyping, longitudinal prognostic modelling, multimodal biomarker integration, and phenotype-enriched interventional trials to determine whether targeting hyperexcitability can alter disease trajectories.